Predicted ferredoxin hydrogenase decline accompanies gut microbiome diversity loss during vonoprazan treatment: an exploratory sub-analysis of a randomized trial

Background Strong gastric acid suppression alters the gut microbiota, but the functional meaning of the resulting loss of bacterial diversity remains unclear. Methods We performed an exploratory sub-analysis of a randomized, double-blind, placebo-controlled pilot trial of 1-kestose during eight weeks of vonoprazan treatment. The analysis included 24 participants with matched baseline fasting breath-gas measurements, baseline and week-8 16S rRNA profiles, PICRUSt2-predicted Enzyme Commission abundances, and fecal short-chain fatty acids. Three consecutive baseline breath measurements were summarized by their participant-level median. Predicted Ferredoxin hydrogenase abundance was normalized per million predicted EC counts. Results Baseline breath H₂ measurements were repeatable (ICC [2, 1] = 0.857), and higher predicted Ferredoxin hydrogenase abundance was associated with higher median breath H₂ after adjustment for simultaneously measured median breath CO (β = 3.979 ppb per RPM; 95% CI, 0.253–7.704; P = 0.037). Predicted Ferredoxin hydrogenase abundance decreased in the placebo group (median change, − 92.6 RPM; q = 0.006) but did not show a statistically significant within-group decrease in the 1-kestose group (median change, − 20.0 RPM; q = 0.500). Changes in predicted Ferredoxin hydrogenase abundance correlated positively with changes in Simpson diversity (Spearman ρ = 0.420; P = 0.041), while cross-sectional values at either time point were not associated. Fecal short-chain fatty acids did not provide independent positive validation of the hydrogenase signal. Conclusions These findings suggest that vonoprazan-associated diversity loss was accompanied by a decline in predicted ferredoxin-linked hydrogen-metabolism potential and that 1-kestose may attenuate this functional change. Trial registration University Hospital Medical Information Network Clinical Trials Registry (UMINCTR), UMIN000028803 registered 24 August 2017. Japan Registry of Clinical Trials (jRCT), jRCTs041190016 registered 10 April 2019.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-19
DOI
https://doi.org/10.21203/rs.3.rs-10992142/v1
Primary Topic
Gut microbiota and health
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Predicted ferredoxin hydrogenase decline accompanies gut microbiome diversity loss during vonoprazan treatment: an exploratory sub-analysis of a randomized trial

Takashi Honda, Shinya Yokoyama, Takeshi Yamamura, Yosuke Inukai et al.
Research Square
Gut microbiota and health
preprint

Predicted ferredoxin hydrogenase decline accompanies gut microbiome diversity loss during vonoprazan treatment: an exploratory sub-analysis of a randomized trial

Takashi Honda, Shinya Yokoyama, Takeshi Yamamura, Yosuke Inukai, Hiroki Kawashima, Kenta Yamamoto, Yoji Ishizu, Atsushi Hashizume, Kazuhiro Furukawa, Kazuki Sahara, Norihiro Imai, Takuya Ishikawa, Yoshihiro Kadota, Yoshihisa Takada, Takanori Ito
preprint en

Abstract

Background Strong gastric acid suppression alters the gut microbiota, but the functional meaning of the resulting loss of bacterial diversity remains unclear. Methods We performed an exploratory sub-analysis of a randomized, double-blind, placebo-controlled pilot trial of 1-kestose during eight weeks of vonoprazan treatment. The analysis included 24 participants with matched baseline fasting breath-gas measurements, baseline and week-8 16S rRNA profiles, PICRUSt2-predicted Enzyme Commission abundances, and fecal short-chain fatty acids. Three consecutive baseline breath measurements were summarized by their participant-level median. Predicted Ferredoxin hydrogenase abundance was normalized per million predicted EC counts. Results Baseline breath H₂ measurements were repeatable (ICC [2, 1] = 0.857), and higher predicted Ferredoxin hydrogenase abundance was associated with higher median breath H₂ after adjustment for simultaneously measured median breath CO (β = 3.979 ppb per RPM; 95% CI, 0.253–7.704; P = 0.037). Predicted Ferredoxin hydrogenase abundance decreased in the placebo group (median change, − 92.6 RPM; q = 0.006) but did not show a statistically significant within-group decrease in the 1-kestose group (median change, − 20.0 RPM; q = 0.500). Changes in predicted Ferredoxin hydrogenase abundance correlated positively with changes in Simpson diversity (Spearman ρ = 0.420; P = 0.041), while cross-sectional values at either time point were not associated. Fecal short-chain fatty acids did not provide independent positive validation of the hydrogenase signal. Conclusions These findings suggest that vonoprazan-associated diversity loss was accompanied by a decline in predicted ferredoxin-linked hydrogen-metabolism potential and that 1-kestose may attenuate this functional change. Trial registration University Hospital Medical Information Network Clinical Trials Registry (UMINCTR), UMIN000028803 registered 24 August 2017. Japan Registry of Clinical Trials (jRCT), jRCTs041190016 registered 10 April 2019.

Research Square
B Food Science (Japan) (JP), Nagoya University (JP)
Gut microbiota and health
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon